167 related articles for article (PubMed ID: 25674720)
1. Translational research in the National Cancer Institute's cooperative groups.
Symmans WF
Clin Adv Hematol Oncol; 2014 Nov; 12(11):785-7. PubMed ID: 25674720
[No Abstract] [Full Text] [Related]
2. Learning from exceptional drug responders.
Mullard A
Nat Rev Drug Discov; 2014 Jun; 13(6):401-2. PubMed ID: 24875081
[No Abstract] [Full Text] [Related]
3. American Society of Clinical Oncology Developing First Clinical Trial.
Brower V
J Natl Cancer Inst; 2015 Nov; 107(11):djv356. PubMed ID: 26538625
[No Abstract] [Full Text] [Related]
4. Clinical cancer advances 2011: Annual Report on Progress Against Cancer from the American Society of Clinical Oncology.
Vogelzang NJ; Benowitz SI; Adams S; Aghajanian C; Chang SM; Dreyer ZE; Janne PA; Ko AH; Masters GA; Odenike O; Patel JD; Roth BJ; Samlowski WE; Seidman AD; Tap WD; Temel JS; Von Roenn JH; Kris MG
J Clin Oncol; 2012 Jan; 30(1):88-109. PubMed ID: 22147736
[TBL] [Abstract][Full Text] [Related]
5. Institutional profile: Developing and evaluating new drugs for cancer treatment: perspectives from the US National Cancer Institute.
Trimble EL; Abrams JS; Ansher SS; Smith MA; Zwiebel JA; Tomaszewski JE
Future Med Chem; 2010 Apr; 2(4):555-9. PubMed ID: 21426005
[No Abstract] [Full Text] [Related]
6. Personalized-medicine trials on the rise.
Benowitz S
J Natl Cancer Inst; 2012 Oct; 104(19):1425-6. PubMed ID: 23008496
[No Abstract] [Full Text] [Related]
7. The effect on drug development of the National Cancer Institute's Cancer Therapy Evaluation Program.
Zwiebel J
Clin Adv Hematol Oncol; 2016 Mar; 14(3):157-9. PubMed ID: 27058027
[No Abstract] [Full Text] [Related]
8. Clinical development of anticancer agents--a National Cancer Institute perspective.
Marsoni S; Wittes R
Cancer Treat Rep; 1984 Jan; 68(1):77-85. PubMed ID: 6362870
[No Abstract] [Full Text] [Related]
9. Danish Translation and Linguistic Validation of the U.S. National Cancer Institute's Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE).
Bæksted C; Nissen A; Pappot H; Bidstrup PE; Mitchell SA; Basch E; Dalton SO; Johansen C
J Pain Symptom Manage; 2016 Aug; 52(2):292-7. PubMed ID: 27090851
[TBL] [Abstract][Full Text] [Related]
10. Supporting quality and patient safety in cancer clinical trials.
Badalucco S; Reed KK
Clin J Oncol Nurs; 2011 Jun; 15(3):263-5. PubMed ID: 21624861
[TBL] [Abstract][Full Text] [Related]
11. The National Cancer Institute Experimental Therapeutics program.
Doroshow JH
Clin Adv Hematol Oncol; 2010 Jun; 8(6):403-4. PubMed ID: 20733549
[No Abstract] [Full Text] [Related]
12. NCI-MATCH launch highlights new trial design in precision-medicine era.
McNeil C
J Natl Cancer Inst; 2015 Jul; 107(7):. PubMed ID: 26142446
[No Abstract] [Full Text] [Related]
13. The National Cancer Institute's Efforts in Promoting Research in the Tumor Microenvironment.
Kuhn NZ; Woodhouse EC; Mohla S
Cancer J; 2015; 21(4):263-6. PubMed ID: 26222077
[TBL] [Abstract][Full Text] [Related]
14. More trials, fewer tribulations.
Eisenstein M
Sci Am; 2014 Jul; 311(1):S9-11. PubMed ID: 24974700
[No Abstract] [Full Text] [Related]
15. National Cancer Institute's support of research to further integrative oncology practice.
White JD
J Natl Cancer Inst Monogr; 2014 Nov; 2014(50):286-7. PubMed ID: 25749590
[No Abstract] [Full Text] [Related]
16. Update on the National Cancer Institute's clinical trials cooperative group program.
Wallner PE
J Am Coll Radiol; 2004 Nov; 1(11):865-6. PubMed ID: 17411719
[No Abstract] [Full Text] [Related]
17. The National Cancer Institute's Drug Development Program.
Schepartz SA
Prog Clin Biol Res; 1985; 197():73-82. PubMed ID: 4070301
[No Abstract] [Full Text] [Related]
18. US National Cancer Institute's new Ras project targets an old foe.
Thompson H
Nat Med; 2013 Aug; 19(8):949-50. PubMed ID: 23921727
[No Abstract] [Full Text] [Related]
19. NCI-MATCH trial pushes cancer umbrella trial paradigm.
Mullard A
Nat Rev Drug Discov; 2015 Aug; 14(8):513-5. PubMed ID: 26228747
[No Abstract] [Full Text] [Related]
20. Commentary. Management of the National Cancer Institute's drug research program through application of the linear array concept.
Rothenberg L; Terselic RA
Cancer Chemother Rep; 1970 Oct; 54(5):303-10. PubMed ID: 5514618
[No Abstract] [Full Text] [Related]
[Next] [New Search]
